Goldman Sachs-backed Attovia eyes $731.5 million valuation in upsized US IPO
Attovia Therapeutics, a biopharma company, said it is targeting a $731.5 million valuation in an upsized US IPO. It plans to raise $289 million by selling 17 million shares at $17 each, after previously targeting up to $212.5 million. Goldman Sachs-affiliated entity will hold about 5.7%. It will list on Nasdaq as ATTO.
How this was made
The 30-second read
Why it matters
The disclosed upsized offering size, fixed price per share, and targeted valuation provide a fresh, tradable reference for IPO demand and expected first-day sentiment.
Market read
This is a primary IPO disclosure with specific terms (shares, price, valuation target) that can drive positioning around IPO pricing and early trading.
What to watch
The article does not provide trial readouts or regulatory milestones; post-IPO performance may hinge on future data rather than IPO demand.
Background
Attovia Therapeutics, founded in 2023, is developing biologic therapies using its ATTOBODY platform and is seeking an upsized IPO on Nasdaq.
Ticker impact
Attovia Therapeutics targets a $731.5 million valuation in an upsized US IPO, listing on Nasdaq under symbol ATTO.
Likely positive bias into pricing and first-day trading, but volatility risk remains typical for pre-revenue biopharma IPOs.
The article discloses concrete IPO size, price, and valuation target plus Goldman-affiliated ownership, which are direct inputs to demand and pricing expectations.
Market effects
Signals continued investor appetite for immune-disease biopharma listings, potentially supporting sentiment for similar pre-commercial names.
US biotech IPO pipeline sentiment, mainly affecting Nasdaq-listed growth/biotech peers.
Limited direct global spillover beyond biotech IPO risk appetite.
Counterpoint
A higher valuation target can also imply more dilution and higher hurdle rates, which may cap upside if clinical progress is not imminent.
Key entities
- companyAttovia Therapeutics
Biopharmaceutical company targeting a $731.5 million valuation in an upsized Nasdaq IPO under ticker ATTO.
- investorGoldman Sachs-affiliated entity
Will own about a 5.7% stake in Attovia, per the company filing.
- venueNasdaq Global Market
Planned listing venue for Attovia’s IPO.
